Cargando…
A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
BACKGROUND: Friedreich's ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet reported frataxin protein and mRNA levels in a large coh...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055871/ https://www.ncbi.nlm.nih.gov/pubmed/21412413 http://dx.doi.org/10.1371/journal.pone.0017627 |
_version_ | 1782200153077186560 |
---|---|
author | Saccà, Francesco Puorro, Giorgia Antenora, Antonella Marsili, Angela Denaro, Alessandra Piro, Raffaele Sorrentino, Pierpaolo Pane, Chiara Tessa, Alessandra Brescia Morra, Vincenzo Cocozza, Sergio De Michele, Giuseppe Santorelli, Filippo M. Filla, Alessandro |
author_facet | Saccà, Francesco Puorro, Giorgia Antenora, Antonella Marsili, Angela Denaro, Alessandra Piro, Raffaele Sorrentino, Pierpaolo Pane, Chiara Tessa, Alessandra Brescia Morra, Vincenzo Cocozza, Sergio De Michele, Giuseppe Santorelli, Filippo M. Filla, Alessandro |
author_sort | Saccà, Francesco |
collection | PubMed |
description | BACKGROUND: Friedreich's ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet reported frataxin protein and mRNA levels in a large cohort of FRDA patients, carriers and controls. METHODOLOGY/PRINCIPAL FINDINGS: We enrolled 24 patients with classic FRDA phenotype (cFA), 6 late onset FRDA (LOFA), all homozygous for GAA expansion, 5 pFA cases who harbored the GAA expansion in compound heterozygosis with FXN point mutations (namely, p.I154F, c.482+3delA, p.R165P), 33 healthy expansion carriers, and 29 healthy controls. DNA was genotyped for GAA expansion, mRNA/FXN was quantified in real-time, and frataxin protein was measured using lateral-flow immunoassay in peripheral blood mononuclear cells (PBMCs). Mean residual levels of frataxin, compared to controls, were 35.8%, 65.6%, 33%, and 68.7% in cFA, LOFA, pFA and healthy carriers, respectively. Comparison of both cFA and pFA with controls resulted in 100% sensitivity and specificity, but there was overlap between LOFA, carriers and controls. Frataxin levels correlated inversely with GAA1 and GAA2 expansions, and directly with age at onset. Messenger RNA expression was reduced to 19.4% in cFA, 50.4% in LOFA, 52.7% in pFA, 53.0% in carriers, as compared to controls (p<0.0001). mRNA levels proved to be diagnostic when comparing cFA with controls resulting in 100% sensitivity and specificity. In cFA and LOFA patients mRNA levels correlated directly with protein levels and age at onset, and inversely with GAA1 and GAA2. CONCLUSION/SIGNIFICANCE: We report the first explorative study on combined frataxin and mRNA levels in PBMCs from a cohort of FRDA patients, carriers and healthy individuals. Lateral-flow immunoassay differentiated cFA and pFA patients from controls, whereas determination of mRNA in q-PCR was sensitive and specific only in cFA. |
format | Text |
id | pubmed-3055871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30558712011-03-16 A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design Saccà, Francesco Puorro, Giorgia Antenora, Antonella Marsili, Angela Denaro, Alessandra Piro, Raffaele Sorrentino, Pierpaolo Pane, Chiara Tessa, Alessandra Brescia Morra, Vincenzo Cocozza, Sergio De Michele, Giuseppe Santorelli, Filippo M. Filla, Alessandro PLoS One Research Article BACKGROUND: Friedreich's ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet reported frataxin protein and mRNA levels in a large cohort of FRDA patients, carriers and controls. METHODOLOGY/PRINCIPAL FINDINGS: We enrolled 24 patients with classic FRDA phenotype (cFA), 6 late onset FRDA (LOFA), all homozygous for GAA expansion, 5 pFA cases who harbored the GAA expansion in compound heterozygosis with FXN point mutations (namely, p.I154F, c.482+3delA, p.R165P), 33 healthy expansion carriers, and 29 healthy controls. DNA was genotyped for GAA expansion, mRNA/FXN was quantified in real-time, and frataxin protein was measured using lateral-flow immunoassay in peripheral blood mononuclear cells (PBMCs). Mean residual levels of frataxin, compared to controls, were 35.8%, 65.6%, 33%, and 68.7% in cFA, LOFA, pFA and healthy carriers, respectively. Comparison of both cFA and pFA with controls resulted in 100% sensitivity and specificity, but there was overlap between LOFA, carriers and controls. Frataxin levels correlated inversely with GAA1 and GAA2 expansions, and directly with age at onset. Messenger RNA expression was reduced to 19.4% in cFA, 50.4% in LOFA, 52.7% in pFA, 53.0% in carriers, as compared to controls (p<0.0001). mRNA levels proved to be diagnostic when comparing cFA with controls resulting in 100% sensitivity and specificity. In cFA and LOFA patients mRNA levels correlated directly with protein levels and age at onset, and inversely with GAA1 and GAA2. CONCLUSION/SIGNIFICANCE: We report the first explorative study on combined frataxin and mRNA levels in PBMCs from a cohort of FRDA patients, carriers and healthy individuals. Lateral-flow immunoassay differentiated cFA and pFA patients from controls, whereas determination of mRNA in q-PCR was sensitive and specific only in cFA. Public Library of Science 2011-03-11 /pmc/articles/PMC3055871/ /pubmed/21412413 http://dx.doi.org/10.1371/journal.pone.0017627 Text en Saccà et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Saccà, Francesco Puorro, Giorgia Antenora, Antonella Marsili, Angela Denaro, Alessandra Piro, Raffaele Sorrentino, Pierpaolo Pane, Chiara Tessa, Alessandra Brescia Morra, Vincenzo Cocozza, Sergio De Michele, Giuseppe Santorelli, Filippo M. Filla, Alessandro A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design |
title | A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design |
title_full | A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design |
title_fullStr | A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design |
title_full_unstemmed | A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design |
title_short | A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design |
title_sort | combined nucleic acid and protein analysis in friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055871/ https://www.ncbi.nlm.nih.gov/pubmed/21412413 http://dx.doi.org/10.1371/journal.pone.0017627 |
work_keys_str_mv | AT saccafrancesco acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT puorrogiorgia acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT antenoraantonella acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT marsiliangela acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT denaroalessandra acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT piroraffaele acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT sorrentinopierpaolo acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT panechiara acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT tessaalessandra acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT bresciamorravincenzo acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT cocozzasergio acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT demichelegiuseppe acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT santorellifilippom acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT fillaalessandro acombinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT saccafrancesco combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT puorrogiorgia combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT antenoraantonella combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT marsiliangela combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT denaroalessandra combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT piroraffaele combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT sorrentinopierpaolo combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT panechiara combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT tessaalessandra combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT bresciamorravincenzo combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT cocozzasergio combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT demichelegiuseppe combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT santorellifilippom combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign AT fillaalessandro combinednucleicacidandproteinanalysisinfriedreichataxiaimplicationsfordiagnosispathogenesisandclinicaltrialdesign |